A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization

本项目的目标是开发一种定量分子乳腺成像PET(QMBI-PET)。 扫描仪改进乳腺癌治疗与个别患者匹配的方式 通过在诊断之间的机会窗口期间提供治疗效果的评估 以及手术切除。美国超过25万名患有侵袭性疾病的女性开始接受治疗 每年都有乳腺癌的治疗。2016年，大约有4万人死于乳腺癌。 不幸的是，尽管靶向治疗取得了成功，但患者的复发率 表达靶点并接受这些疗法肯定仍接近50% 表型。这些药物可能非常昂贵，而且会产生毒副作用。目前有68家 FDA批准了乳腺癌药物，这是所有癌症中最多的。 宠物拥有巨大的希望来改进治疗选择，从而使患者最终免于 无效的药物，并更快地将他们引导到有效的方案，从而改善患者 结果，并通过更有效的治疗选择过程降低成本。然而，所有的 到目前为止，使用正电子发射计算机断层扫描评估治疗反应的研究仅限于定量 临床全身PET扫描仪的准确性 紧凑、低成本、高分辨率和定量准确的PET成像扫描仪将 帮助医生为乳腺癌患者选择有效的治疗方法。早些时候 对治疗效果的评估将有助于治疗医生对患者的个体化 治疗：在新辅助治疗的环境下或在诊断和治疗之间的机会之窗 手术后，将拍摄基线(治疗前)PET图像，然后，在短时间的 对于靶向治疗，将使用第二次正电子发射计算机断层扫描来评估治疗反应。这将是 用于指导术后治疗的选择性和侵袭性。 要使这种治疗模式被广泛接受和广泛使用，最低限度的可行 商用扫描仪需要更高的分辨率、更紧凑、更便宜 标准全身PET扫描仪。此外，还需要高水平的定量准确性。 我们提出了一种高分辨率定量分子乳腺成像PET(QMBI-PET)扫描仪， 它使用先进的探测器架构和基于统计的3D成像来获取 高灵敏度、高分辨率的图像。这一阶段申请的结果将是 功能实验室测试的单环原型扫描仪，具有临床可行性的初步数据 为这一开发的下一个阶段的商业化提供证据。

The goal of this project is to develop a quantitative molecular breast imaging PET (QMBI-PET) scanner to improve the way in which breast cancer therapies are matched to individual patients by providing evaluation of therapy efficacy during the window of opportunity between diagnosis and surgical resection. More than 250,000 women in the US with invasive disease start therapy for breast cancer each year. In 2016 approximately 40,000 deaths will result from breast cancer. Unfortunately, despite the successes of targeted therapies, the relapse rate in patients expressing the targets and receiving these therapies still approaches 50% for certain phenotypes. The drugs can be very costly, and carry toxic side effects. There are currently 68 FDA approved breast cancer drugs, the most of any cancer. PET holds great promise to improve therapy selection, thereby sparing patients from ultimately ineffective drugs and directing them more quickly to effective regimens, thus improving patient outcomes, and reducing costs via a more efficient therapy selection process. However, all of the studies thus far using PET to assess therapy response have been limited to the quantitative accuracy of clinical whole-body PET scanners A compact, lower-cost, high resolution, and quantitatively accurate PET imaging scanner will help inform the physician's choices of effective therapies for breast cancer patients. Early evaluation of a therapy's effectiveness will help the treating physician individualize a patient's treatment: In the neo-adjuvant setting or the window of opportunity between diagnosis and surgery, a baseline (pre-treatment) PET image will be taken, then, after a short regimen of a targeted therapy, a second PET scan will be used to evaluate response to treatment. This will be used to guide selection and aggressiveness of post-surgery therapy. For this treatment paradigm to become broadly accepted and widely used, the minimum viable commercial scanner needs to be higher resolution, more compact, and less expensive than standard whole-body PET scanners. In addition a high level of quantitative accuracy is needed. We propose a high-resolution quantitative molecular breast imaging PET (QMBI-PET) scanner, which uses a an advanced detector architecture and statistical-based 3D imaging to acquire high-sensitivity, high-resolution images. The outcome of this Phase-I application will be a functional laboratory tested single-ring prototype scanner, with initial data on clinical feasibility to provide evidence for commercialization in the following phase of this development.